Advertisement
Screener

ACLARION, INC. (ACON) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

ACLARION, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

ACLARION, INC. (ACON) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 481.92 thousand shares for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-06-12.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2023-06-12

  • ACLARION, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 481.92K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month
2022-12-31481.92K shares
10-K/A · filed 2023-06-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Advanced Biomed Inc. (ADVB)$0.009B
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
BioNexus Gene Lab Corp (BGLC)$0.004B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45